
Kraft Heinz pulling certain artificial dyes from its US products in 2027
The move comes nearly two months after U.S. health officials said that they would urge foodmakers to phase out petroleum-based artificial colors in the nation's food supply.
Kraft Heinz said Tuesday that almost 90% of its U.S. products already don't contain food, drug & cosmetic colors, but that the products that do still use the dyes will have them removed by the end of 2027. FD&C colors are synthetic additives that are approved by the U.S. Food and Drug Administration for use in food, drugs and cosmetics.
The company said that it will instead use natural colors for the products.
'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio," Pedro Navio, North America President at Kraft Heinz, said in a statement.
Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup.
The company plans to work with licensees of its brands to encourage them to remove the dyes.
In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry.
Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.'
The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats.
Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods.
Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 hours ago
- Globe and Mail
Pfizer's Elranatamab Study: Continued Access for Multiple Myeloma Patients
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting an Elranatamab Post Trial Access Study for participants with Multiple Myeloma, officially titled 'ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES'. The study aims to provide continued access to elranatamab for patients who have shown clinical benefit in previous trials. This is significant as it supports ongoing treatment for patients with limited options. The intervention being tested is Elranatamab, a drug designed as a heterodimeric humanized full-length bispecific IgG2 kappa antibody. It targets BCMA on Multiple Myeloma cells and CD3 on T cells, aiming to enhance the immune response against cancer cells. The study is designed as an open-label, single-arm trial with no masking, focusing on treatment. All participants receive Elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination, or commercial availability of the drug in their country. The study began on October 3, 2023, and is currently recruiting. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study's progress and understanding its timeline. This update may positively influence Pfizer's stock performance by demonstrating continued commitment to innovative cancer treatments. It may also impact investor sentiment favorably, especially in the context of competitive advancements in cancer therapies. The study is ongoing, with further details available on the ClinicalTrials portal.


Globe and Mail
3 hours ago
- Globe and Mail
TruBridge Announces Second Quarter 2025 Conference Call to Be Held Friday, August 8, 2025
TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that it will release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the market closes. The Company will host a conference call at 7:30 a.m. Central Time, 8:30 a.m. Eastern Time on Friday, August 8, 2025. To access this interactive teleconference, dial (877) 407-0890 and request connection to the TruBridge earnings conference call. A live broadcast of TruBridge's conference call will also be available online at the Company's investor relations website, The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast. About TruBridge TruBridge proudly supports rural and community hospitals and providers in their efforts to stay strong, independent, and deeply rooted in the communities they serve. Backed by more than 45 years of healthcare experience and trusted by over 1,500 clients nationwide, we offer a mix of technology, services, and strategic expertise — including revenue cycle management, electronic health records (EHR) and analytics — all designed singularly for the realities of rural and community healthcare. With a steadfast commitment to keeping care local, TruBridge helps hospitals flourish as the economic heart of their communities, delivering high-quality, personal care close to home. For more information, visit


Globe and Mail
4 hours ago
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly & Co (LLY) TD Cowen analyst Steve Scala maintained a Buy rating on Eli Lilly & Co today and set a price target of $960.00. The company's shares closed last Thursday at $763.28. According to Scala is a 4-star analyst with an average return of 6.7% and a 60.4% success rate. Scala covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, GlaxoSmithKline, and Merck & Company. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1028.80 average price target, which is a 37.7% upside from current levels. In a report issued on July 17, TR | OpenAI – 4o also upgraded the stock to Buy with a $885.00 price target. AbbVie (ABBV) In a report released today, Matt Phipps from William Blair maintained a Buy rating on AbbVie. The company's shares closed last Thursday at $194.50. According to Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 41.1% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Vertex Pharmaceuticals. ;'> Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $212.46, which is a 7.8% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $206.00 price target.